By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today reported that its second-quarter molecular diagnostics sales increased around 19 percent year over year.

The firm posted total molecular diagnostics sales of $105 million for the three-month period ended June 30, compared to $89 million for Q2 2010. Of the $105 million, $45 million of the sales came from the US with the remainder coming from international markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.